Loading
Given as first treatment, selpercatinib more than doubled the time to progression compared with platinum-pemetrexed chemotherapy plus pembrolizumab in RET fusion-positive lung cancer, and protected against brain metastases.
Phase 3 trial of 261 patients with untreated advanced RET fusion-positive non-squamous non-small-cell lung cancer randomised to selpercatinib or platinum-pemetrexed with or without pembrolizumab.
Median progression-free survival was 24.8 versus 11.2 months (hazard ratio 0.46) in the intention-to-exclude-pembrolizumab population, response 84 versus 65 percent, and the cumulative incidence of central nervous system progression was lower with selpercatinib.
Selpercatinib is the established first-line treatment for RET fusion-positive lung cancer, and the trial adds to evidence that targeted therapy should precede chemo-immunotherapy in driver-positive disease.
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer, New England Journal of Medicine.
Shares LIBRETTO-431, Selpercatinib, RET fusion-positive non-small-cell lung cancer.
Shares LIBRETTO-431, Selpercatinib, Pembrolizumab.
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.
Shares LIBRETTO-431, RET fusion-positive non-small-cell lung cancer.
Shares LIBRETTO-431, Selpercatinib.
Shares Selpercatinib, RET fusion-positive non-small-cell lung cancer.